Juanjuan Zhao1, Quan Yuan2,3, Haiyan Wang1, Wei Liu2,3, Xuejiao Liao1, Yingying Su2,3, Xin Wang1, Jing Yuan4, Tingdong Li2,3, Jinxiu Li5, Shen Qian1, Congming Hong2,3, Fuxiang Wang4, Yingxia Liu4,6, Zhaoqin Wang6, Qing He6, Zhiyong Li3, Bin He2,3, Tianying Zhang2,3, Yang Fu7, Shengxiang Ge2,3, Lei Liu1,6, Jun Zhang2,3, Ningshao Xia2,3, Zheng Zhang1,6. 1. Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, China. 2. The State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Collaborative Innovation Center of Biologic Products, School of Public Health and School of Life Science, Xiamen University, Xiamen, China. 3. School of Public Health, Xiamen University, Xiamen, China. 4. Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, China. 5. Department of Critical Care Medicine, Shenzhen Third People's Hospital, Shenzhen, China. 6. The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, China. 7. School of Medicine, Southern University of Science and Technology, Shenzhen, China.
Abstract
BACKGROUND: The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patients remains largely unknown, and the clinical value of antibody testing has not been fully demonstrated. METHODS: 173 patients with SARS-CoV-2 infection were enrolled. Their serial plasma samples (n = 535) collected during hospitalization were tested for total antibodies (Ab), IgM, and IgG against SARS-CoV-2. The dynamics of antibodies with disease progress were analyzed. RESULTS: Among 173 patients, the seroconversion rates for Ab, IgM, and IgG were 93.1%, 82.7%, and 64.7%, respectively. The reason for the negative antibody findings in 12 patients might be due to the lack of blood samples at the later stage of illness. The median seroconversion times for Ab, IgM, and then IgG were days 11, 12, and 4, respectively. The presence of antibodies was <40% among patients within 1 week of onset, and rapidly increased to 100.0% (Ab), 94.3% (IgM), and 79.8% (IgG) by day 15 after onset. In contrast, RNA detectability decreased from 66.7% (58/87) in samples collected before day 7 to 45.5% (25/55) during days 15-39. Combining RNA and antibody detection significantly improved the sensitivity of pathogenic diagnosis for COVID-19 (P < .001), even in the early phase of 1 week from onset (P = .007). Moreover, a higher titer of Ab was independently associated with a worse clinical classification (P = .006). CONCLUSIONS: Antibody detection offers vital clinical information during the course of SARS-CoV-2 infection. The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients.
BACKGROUND: The novel coronavirusSARS-CoV-2 is a newly emerging virus. The antibody response in infectedpatients remains largely unknown, and the clinical value of antibody testing has not been fully demonstrated. METHODS: 173 patients with SARS-CoV-2 infection were enrolled. Their serial plasma samples (n = 535) collected during hospitalization were tested for total antibodies (Ab), IgM, and IgG against SARS-CoV-2. The dynamics of antibodies with disease progress were analyzed. RESULTS: Among 173 patients, the seroconversion rates for Ab, IgM, and IgG were 93.1%, 82.7%, and 64.7%, respectively. The reason for the negative antibody findings in 12 patients might be due to the lack of blood samples at the later stage of illness. The median seroconversion times for Ab, IgM, and then IgG were days 11, 12, and 4, respectively. The presence of antibodies was <40% among patients within 1 week of onset, and rapidly increased to 100.0% (Ab), 94.3% (IgM), and 79.8% (IgG) by day 15 after onset. In contrast, RNA detectability decreased from 66.7% (58/87) in samples collected before day 7 to 45.5% (25/55) during days 15-39. Combining RNA and antibody detection significantly improved the sensitivity of pathogenic diagnosis for COVID-19 (P < .001), even in the early phase of 1 week from onset (P = .007). Moreover, a higher titer of Ab was independently associated with a worse clinical classification (P = .006). CONCLUSIONS: Antibody detection offers vital clinical information during the course of SARS-CoV-2 infection. The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19patients.
Authors: Pedro N Batalha; Luana S M Forezi; Carolina G S Lima; Fernanda P Pauli; Fernanda C S Boechat; Maria Cecília B V de Souza; Anna C Cunha; Vitor F Ferreira; Fernando de C da Silva Journal: Bioorg Chem Date: 2020-11-19 Impact factor: 5.275
Authors: Daniel Shyu; James Dorroh; Caleb Holtmeyer; Detlef Ritter; Anandhi Upendran; Raghuraman Kannan; Dima Dandachi; Christian Rojas-Moreno; Stevan P Whitt; Hariharan Regunath Journal: Mo Med Date: 2020 May-Jun
Authors: Elizabeth Wilkinson; Anuradha Jetty; Stephen Petterson; Yalda Jabbarpour; John M Westfall Journal: Ann Fam Med Date: 2021-03-11 Impact factor: 5.166
Authors: Raymond T Suhandynata; Melissa A Hoffman; Deli Huang; Jenny T Tran; Michael J Kelner; Sharon L Reed; Ronald W McLawhon; James E Voss; David Nemazee; Robert L Fitzgerald Journal: Clin Chem Date: 2021-01-30 Impact factor: 8.327